Stocks and Investing Stocks and Investing
Tue, November 24, 2020
Mon, November 23, 2020
Fri, November 20, 2020

Colin Bristow Maintained (VRTX) at Strong Buy with Increased Target to $288 on, Nov 20th, 2020


Published on 2024-10-27 14:50:41 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $287 to $288 on, Nov 20th, 2020.

Colin has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 3 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $247 on, Tuesday, November 17th, 2020
  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $257 on, Friday, October 30th, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $249 on, Monday, October 19th, 2020


These are the ratings of the 6 analyists that currently disagree with Colin


  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $285 on, Friday, October 30th, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $307 on, Friday, October 30th, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $277 on, Friday, October 30th, 2020
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $305 on, Friday, July 31st, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $315 on, Friday, July 31st, 2020
Contributing Sources